Core Viewpoint - Tuoxin Pharmaceutical, established in 2005 and listed in 2021, is a leading domestic manufacturer of nucleoside raw materials with significant technological advantages in research and production, presenting investment value [1] Group 1: Business Performance - In Q3 2025, Tuoxin Pharmaceutical reported revenue of 272 million yuan, ranking 41st out of 47 in the industry, while the industry leader, Prolo Pharmaceutical, achieved 7.764 billion yuan [2] - The net profit for the same period was -30.16 million yuan, also ranking 41st, with the industry average net profit being 133 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 9.89%, lower than the previous year's 10.17% and significantly below the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 29.36%, an increase from 25.69% year-on-year, but still below the industry average of 35.38% [3] Group 3: Executive Compensation - Chairman Yang Xining's salary for 2024 is 1.0063 million yuan, a decrease of 20,300 yuan from 2023 [4] - President Yang Shaohua's salary for 2024 is 605,100 yuan, an increase of 164,200 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 10.18% to 18,100, while the average number of circulating A-shares held per account decreased by 9.75% to 4,988.97 [5]

Core Viewpoint - The company, Tuoxin Pharmaceutical, emphasizes its strong position in the antiviral sector with a rich product portfolio and technological expertise in the development, production, and sales of pharmaceutical health products [1] Group 1: Company Overview - Tuoxin Pharmaceutical is identified as a high-tech enterprise focused on the research, development, production, and sales of pharmaceutical health products [1] - The company has a significant product reserve in the antiviral field, showcasing its capability and experience in this area [1] Group 2: Key Products - The core product, Ribavirin raw material, is highlighted as an important component of antiviral drugs and is classified as a broad-spectrum, potent antiviral medication [1] - Additionally, the company produces Cytidine and 5-Fluorouracil, which are key intermediates for synthesizing various antiviral drugs [1]

Core Viewpoint - Toxin Pharmaceutical (301089) announced the establishment of a wholly-owned subsidiary, Toxin Pharmaceutical (Inner Mongolia) Co., Ltd., to leverage local energy advantages for optimizing cost structure and enhancing overall development strategy [1] Group 1: Company Strategy - The subsidiary will be registered in Hohhot, Inner Mongolia, with a registered capital of 50 million yuan, focusing on the research, production, and sales of fermentation-related products [1] - The company has a mature microbial fermentation technology platform and extensive experience in traditional mutagenesis and molecular breeding, which supports its operational capabilities [1] Group 2: Market and Economic Context - Inner Mongolia is recognized as a key energy supply base in China, with abundant wind, solar, and thermal power resources, providing significant energy endowment advantages [1] - The low electricity prices in Inner Mongolia are expected to effectively reduce energy costs, which are critical to the company's core competitiveness due to the high energy consumption characteristics of the fermentation process [1]

Core Viewpoint - Tuo Xin Pharmaceutical (301089) announced the election of Dong Hongjie and Yang Dejie as independent director candidates for the fifth board of directors [1] Company Summary - Tuo Xin Pharmaceutical has made a significant governance decision by proposing the election of two independent directors, which may enhance its board's oversight and strategic direction [1]

Core Viewpoint - The company,拓新药业, reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating ongoing financial struggles since its market entry in 2021 [1][2] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 272 million yuan, a year-on-year decrease of 16.64% [1] - The net profit attributable to shareholders was a loss of 30.16 million yuan, representing a year-on-year decline of 1036.53% [1] - In Q3 2025, revenue was 89.65 million yuan, down 16.21% year-on-year, with a net profit loss of 11.88 million yuan, a staggering decline of 1258.62% [1] Industry Context - The pharmaceutical manufacturing industry is undergoing profound changes, with revenue for large-scale pharmaceutical manufacturing declining by 1.2% to 1.22752 trillion yuan in the first half of 2025, and total profits down 2.8% to 176.69 billion yuan [2] - The industry faces challenges from intensified competition, regulatory reforms, and cost control pressures, particularly affecting the raw materials and intermediates sector [2] Company Strategy - The company plans to establish a wholly-owned subsidiary in Inner Mongolia to leverage local energy advantages, particularly low electricity costs, to enhance its competitive edge [3] - The new subsidiary will focus on the research, production, and sales of fermentation-related products, aligning with the company's core business [2][3] - The company acknowledges potential uncertainties in expected returns from this investment due to various factors, including industry policies and market conditions [3]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the third quarter of 2025 compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 89.65 million yuan, a year-on-year decrease of 16.21% [1] - The net loss attributable to shareholders was 11.88 million yuan, with a year-on-year increase in loss of 1258.62% [1] - Basic earnings per share showed a loss of 0.09 yuan [1] Year-to-Date Performance - For the first three quarters of 2025, the company reported a total revenue of 272 million yuan, reflecting a year-on-year decline of 16.64% [1] - The net loss attributable to shareholders for the same period was 30.16 million yuan, compared to a net loss of 2.65 million yuan in the previous year [1] - Basic earnings per share for the first three quarters indicated a loss of 0.24 yuan [1]

☑ 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办 法》和深圳证券交易所业务规则规定的独立董事任职资格和 条 件。 上市公司独立董事提名人声明与承诺 提名人拓新药业集团股份有限公司董事会现就提名杨德杰 为拓新药业集团股份有限公司第五届董事会独立董事候选人发 表公开声明。被提名人已书面同意作为拓新药业集团股份有限 公司第五届董事会独立董事候选人（参见该独立董事候选人声 明）。本次提名是在充分了解被提名人职业、学历、职称、详 细的工作经历、全部兼职、有无重大失信等不良记录等情况后 作出的，本提名人认为被提名人符合相关法律、行政法规、部 门规章、规范性文件和深圳证券交易所业务规则对独立董事候 选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过拓新药业集团股份有限公司第五届 董事会提名委员会或者独立董事专门会议资格审查，提名人与 被提名人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 ☑ 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 六、被提名人担任独立董事不会违反《中华人 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-054 拓新药业集团股份有限公司 关于独立董事任期届满辞职暨补选独立董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、独立董事辞职情况 拓新药业集团股份有限公司（以下简称"公司"）董事会于近日分别收到 公司独立董事靳焱顺先生和刘建伟先生的书面辞职报告，靳焱顺先生和刘建伟 先生自2019年11月30日起担任公司独立董事，连续任职时间即将满六年，分别 申请辞去公司第五届董事会独立董事及相关董事会专门委员会委员职务，辞职 后靳焱顺先生和刘建伟先生不再担任公司任何职务。 截至本公告披露日，靳焱顺先生和刘建伟先生未持有本公司股份。靳焱顺 先生和刘建伟先生的离职将导致公司独立董事人数低于董事会成员的三分之一， 根据《公司法》《公司章程》等有关规定，靳焱顺先生和刘建伟先生的离职将 在公司股东会选举产生新任独立董事后生效。在此之前，靳焱顺先生和刘建伟 先生将继续按照有关法律法规及《公司章程》等的规定，履行其职责。靳焱顺 先生和刘建伟先生在担任公司独立董事期间恪尽职守、勤勉尽责，公司及董事 会对其任职 ...

上市公司独立董事候选人声明与承诺 声明人董红杰作为拓新药业集团股份有限公司第五届董事会 独立董事候选人，已充分了解并同意由提名人拓新药业集团股份 有限公司董事会提名为拓新药业集团股份有限公司（以下简称该 公司）第五届董事会独立董事候选人。现公开声明和保证，本人 与该公司之间不存在任何影响本人独立性的关系，且符合相关法 律、行政法规、部门规章、规范性文件和深圳证券交易所业务规 则对独立董事候选人任职资格及独立性的要求，具体声明并承诺 如下事项： 一、本人已经通过拓新药业集团股份有限公司第五届董事会 提名委员会或者独立董事专门会议资格审查，提名人与本人不存 在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明： 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》 和深圳证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 ☑ 是 □ 否 如否，请详细说明： 五、本人已经参加培训并取得证券交易所认可的相关培训 证明材料（如有）。 □ 是 ☑ 否 二、本人不存在《中华人民共和国公司法》第 ...

一、被提名人已经通过拓新药业集团股份有限公司第五届 董事会提名委员会或者独立董事专门会议资格审查，提名人与 被提名人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 ☑ 是 □ 否 上市公司独立董事提名人声明与承诺 提名人拓新药业集团股份有限公司董事会现就提名董红杰 为拓新药业集团股份有限公司第五届董事会独立董事候选人发 表公开声明。被提名人已书面同意作为拓新药业集团股份有限 公司第五届董事会独立董事候选人（参见该独立董事候选人声 明）。本次提名是在充分了解被提名人职业、学历、职称、详 细的工作经历、全部兼职、有无重大失信等不良记录等情况后 作出的，本提名人认为被提名人符合相关法律、行政法规、部 门规章、规范性文件和深圳证券交易所业务规则对独立董事候 选人任职资格及独立性的要求，具体声明并承诺如下事项： □ 是 ☑ 否 如否，请详细说明：候选人承诺将参加最近一次独立董 事培训并取得深交所认可的独立董事资格证书。 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管 ...